New treatments for HIV that work against drug-resistant strains
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV
This study is testing new, super-strong medicines that aim to stop HIV from spreading, especially in cases where current treatments aren't working well, so that patients can have better and safer options for managing their health.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10977647 on NIH RePORTER |
What this research studies
This research focuses on developing ultrapotent inhibitors that target HIV, including strains resistant to current treatments. The approach involves a novel mechanism that blocks the replication of the virus by interfering with a specific step in the HIV life cycle. Patients may benefit from longer-acting and less toxic therapies that could improve their quality of life and treatment outcomes. The research includes pre-clinical and clinical trials to evaluate the effectiveness and safety of these new drugs.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals living with HIV, especially those who have not responded well to existing treatments.
Not a fit: Patients who are not infected with HIV or those who have already achieved viral suppression with current therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer HIV treatments, particularly for those with drug-resistant strains.
How similar studies have performed: Previous research has shown promise with similar mechanisms targeting HIV, indicating potential for success in this area.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Sarafianos, Stefan G — Emory University
- Study coordinator: Sarafianos, Stefan G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.